TCT 2019: A Preview Of Late-Breaking Trials; Analyst Expectations
Executive Summary
Interventional cardiologists can expect important updates on transcatheter valves and drug-eluting stents during this year's late-breaking trials presented at the annual Transcatheter Cardiovascular Therapeutics meeting next week. They include updates from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.
You may also be interested in...
TCT 2019: Boston Scientific's Acurate Neo TAVR Misses Endpoint In SCOPE I
Boston Scientific is looking ahead to the next-generation Acurate neo2 valve after results of SCOPE I showed worse rates of kidney injury and severe aortic regurgitation in patients treated with the self-expanding Acurate neo valve than in patients treated with Edwards’ Sapien 3 valve.
TCT 2019: Evolve Short DAPT And Model U-SUS Study Show Short DAPT Was Comparable To Longer-Term DAPT
Data from two studies that looked at the safety of three-months dual antiplatelet therapy versus longer-term DAPT therapy, presented on 26 September at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, showed non-inferiority for short-term DAPT.
TCT 2019: IDEAL LM Inconclusive, While Onyx ONE Boosts Polymer-Based DES
Data from two late-breaking drug-eluting stent trials, presented on 26 September at Transcatheter Cardiovascular Therapeutics meeting in San Francisco, prompted mixed reactions from interventional cardiologists.